By Omkar Godbole (All times ET unless indicated otherwise) Bitcoin (BTC) rebounded to almost $90,000, reversing Sunday's drop to trade largely unchanged over 24 hours. The same can be said for the broader market, with both the CoinDesk 20 (CD20) and CoinDesk 80 (CD80) indexes little changed. The only notable winner is the RAIN token, which has added over 6%. BTC's recovery is consistent with the 0.5% gains in futures tied to the S&P 500 and the Nasdaq, and with the continued weak tone in the dollar. "P ...

Core Insights - Enlivex Therapeutics Ltd. will host a virtual fireside chat on December 11, 2025, to discuss its recent $212 million private placement and future plans [1][2][3] - The company is focusing on advancing the clinical development of Allocetra™, a therapy for osteoarthritis, which affects over 32.5 million Americans and 300 million people globally [5] Company Plans - Shai Novik, Executive Chairman, will provide updates on the digital asset treasury strategy centered around RAIN token accumulation [2] - Enlivex aims to offer investors exposure to RAIN as a primary treasury reserve asset [4] Clinical Development - Allocetra™ is designed to treat osteoarthritis, a prevalent joint disease with significant hospitalization rates in the U.S. [5] - There are currently no FDA or EMA approved medications that can halt or reverse joint damage in osteoarthritis patients [5]

Core Insights - Enlivex Therapeutics is raising $212 million in a private placement to become the first publicly traded U.S. company to adopt a blockchain-based prediction markets token, RAIN, as its main treasury reserve asset [1][3] - The RAIN token operates on the Arbitrum blockchain, enabling users to create and trade prediction markets on real-world events [1][2] - Enlivex plans to use the majority of the funds raised to purchase RAIN tokens, viewing the prediction markets space as a strategic growth area [3] Company Developments - Enlivex has a market cap of $22 million on Nasdaq and aims to integrate RAIN tokens into its treasury management strategy [3] - The company is continuing clinical trials for its lead drug candidate, Allocetra, which targets osteoarthritis, a condition affecting over 30 million Americans [4] - Matteo Renzi, former Prime Minister of Italy, is expected to join Enlivex's board following the completion of the deal on November 25 [5] Financial Aspects - The transaction is priced at $1 per share, representing an 11.5% premium over Enlivex's last trading price [5] - Last year, Enlivex's board approved the purchase of up to $1 million in Bitcoin as part of its cash-management strategy [5]